Maximilien Fournier Sourdille
Directeur/Membre du Conseil chez Themis Bioscience GmbH
Profil
Maximilien Fournier Sourdille is currently the Director at MBO+ SAS and the Director at Eye Tech Care SA. He also holds the position of Principal at Omnes Capital SAS since 2017 and is the Deputy Chair-Supervisory Board at Themis Bioscience GmbH.
In the past, he worked as the Director at Thérapixel SA.
Postes actifs de Maximilien Fournier Sourdille
Sociétés | Poste | Début |
---|---|---|
Omnes Capital SAS /Venture/
Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Private Equity Investor | 01/03/2019 |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Directeur/Membre du Conseil | - |
MBO+ SAS
MBO+ SAS Investment ManagersFinance Mbo & Co. Sas is an Independent Private Equity firm founded in 2002. Mbo & Co. Sas is headquartered in Paris. | Private Equity Investor | 01/09/2020 |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Directeur/Membre du Conseil | - |
Anciens postes connus de Maximilien Fournier Sourdille
Sociétés | Poste | Fin |
---|---|---|
Thérapixel SA
Thérapixel SA Packaged SoftwareTechnology Services Thérapixel SA designs software publisher for healthcare facilities. The company was founded by Olivier Clatz and Pierre Fillard in 2013 and is headquartered in Valbonne, France. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 5 |
---|---|
Omnes Capital SAS /Venture/
Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Finance |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Health Technology |
Thérapixel SA
Thérapixel SA Packaged SoftwareTechnology Services Thérapixel SA designs software publisher for healthcare facilities. The company was founded by Olivier Clatz and Pierre Fillard in 2013 and is headquartered in Valbonne, France. | Technology Services |
MBO+ SAS
MBO+ SAS Investment ManagersFinance Mbo & Co. Sas is an Independent Private Equity firm founded in 2002. Mbo & Co. Sas is headquartered in Paris. | Finance |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Health Technology |